滋养外胚层活检用于胚胎植入前遗传学检测对产科和新生儿结局的影响:一项Meta分析
该Meta分析纳入13项研究,比较滋养外胚层活检行胚胎植入前遗传学检测后11,469例活产与常规体外受精或卵胞浆内单精子注射后20,438例活产的产科和新生儿结局。早产汇总比值比为1.12(95%置信区间1.03-1.21),但敏感性分析后差异不存在(比值比0.97,95%置信区间0.84-1.11);低出生体重风险未增加(汇总比值比1.01,95%置信区间0.85-1.20)。结论认为滋养外胚层活检未改变产科或新生儿结局风险,但受限于大量观察性证据,需更多随机对照试验进一步证实。
要点
- 滋养外胚层活检组早产汇总比值比1.12(95%置信区间1.03-1.21),敏感性分析后为0.97(95%置信区间0.84-1.11)。
- 低出生体重风险未增加,汇总比值比1.01(95%置信区间0.85-1.20)。
- 按卵胞浆内单精子注射、冻融移植或单胚胎移植亚组分析,围产期结局无差异。
核心结论
- 与未行胚胎植入前遗传学检测的常规体外受精或卵胞浆内单精子注射相比,滋养外胚层活检行胚胎植入前遗传学检测未改变产科或新生儿结局风险。
- 本研究受限于大量观察性证据,需要更多随机对照试验进一步证实这些发现。
研究设计与样本
- 系统检索MEDLINE、Embase、Web of Science、Cochrane Library和Google Scholar 1990年1月至2022年8月的文献。
- 纳入比较滋养外胚层活检行胚胎植入前遗传学检测与体外受精或卵胞浆内单精子注射后妊娠结局的队列研究、病例对照研究或随机对照试验。
- 共纳入13项研究,滋养外胚层活检组11,469例活产,常规体外受精或卵胞浆内单精子注射组20,438例活产。
- 由2名研究者独立进行文献筛选,观察性研究采用纽卡斯尔-渥太华量表评估质量,随机对照试验采用Cochrane偏倚风险工具第2版评级。
- 存在显著异质性(I²>50%且P<.1)时采用随机效应模型计算汇总比值比和95%置信区间,否则采用固定效应模型。
主要发现
- 滋养外胚层活检组早产比值比高于常规体外受精或卵胞浆内单精子注射组(汇总比值比1.12,95%置信区间1.03-1.21),但敏感性分析后差异不存在(比值比0.97,95%置信区间0.84-1.11)。
- 活检妊娠中低出生体重风险未增加(汇总比值比1.01,95%置信区间0.85-1.20)。
- 活检组与对照组其他产科或新生儿结局风险无显著差异。
- 按卵胞浆内单精子注射、冻融移植或单胚胎移植进行的亚组分析中,活检组与非活检组围产期结局无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究受限于大量观察性证据。
- 需要更多随机对照试验进一步证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to investigate whether trophectoderm biopsy for preimplantation genetic testing is associated with an increased risk of adverse obstetrical and neonatal outcomes compared with conventional in vitro fertilization or intracytoplasmic sperm injection without preimplantation genetic testing. DATA SOURCES: Entries between January 1990 and August 2022 were searched using MEDLINE, Embase, Web of Science, the Cochrane Library, and Google Scholar. STUDY ELIGIBILITY CRITERIA: Publications comparing the outcomes of pregnancies after preimplantation genetic testing using trophectoderm biopsy and in vitro fertilization or intracytoplasmic sperm injection were included. Only human studies with a cohort or case-control design or randomized controlled trials were eligible for inclusion. METHODS: The study selection process was performed independently by 2 investigators. The quality of the observational studies was assessed using the Newcastle-Ottawa Scale, and the Cochrane risk-of-bias tool version 2 was used to grade the level of bias in randomized controlled trials. The pooled odds ratio and 95% confidence interval were calculated using a random-effects model when substantial heterogeneity occurred (indicated by I2 of >50% and P<.1). Otherwise, a fixed-effects model was used. RESULTS: This meta-analysis included 13 studies involving 11,469 live births after preimplantation genetic testing treatment with trophectoderm biopsy before embryo transfer and 20,438 live births after in vitro fertilization or intracytoplasmic sperm injection only. The odds ratio of preterm delivery was higher in the trophectoderm-biopsied group than in the routine in vitro fertilization or intracytoplasmic sperm injection group (pooled odds ratio, 1.12; 95% confidence interval, 1.03-1.21); however, the difference did not exist after sensitivity analysis (odds ratio, 0.97; 95% confidence interval, 0.84-1.11). The risk of low birthweight did not increase among the biopsied pregnancies (pooled odds ratio, 1.01; 95% confidence interval, 0.85-1.20). No marked difference was observed in the risk of other obstetrical or neonatal outcomes between the biopsy and control groups. Furthermore, no difference was noted in the perinatal outcomes between trophectoderm-biopsied and nonbiopsied groups in the subgroup analyses by intracytoplasmic sperm injection, frozen-thawed transfer, or single embryo transfer. CONCLUSION: Trophectoderm biopsy for preimplantation genetic testing treatment did not alter the risk of obstetrical or neonatal outcomes compared with conventional in vitro fertilization or intracytoplasmic sperm injection without preimplantation genetic testing. However, this study was limited by the large observational evidence base, and more randomized controlled trials are needed to further confirm these findings.
引用
- Mao D, Xu J, Sun L, et al. Impact of trophectoderm biopsy for preimplantation genetic testing on obstetric and neonatal outcomes: a meta-analysis. Am J Obstet Gynecol. 2023. PMID: 37595823. doi:10.1016/j.ajog.2023.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。